Cartoon-style illustration of a bispecific antibody bound to a T cell through one binding site and a tumor cell through a second binding site
Multispecific antibodies bind to two or more different epitopes, enabling physically linked multitargeting with a single therapeutic.

Antibody-based therapeutics have revolutionized treatment options for many indications, including cancer, autoimmune and metabolic conditions, and infectious diseases. Although monoclonal antibodies (mAbs) currently account for the majority of biologics approved annually by the FDA,1 mAbs bind to only one target by design. The therapeutic success of mAbs has inspired researchers to push antibody therapeutic technologies toward multifunctionality, turning to bispecific, trispecific, and tetraspecific antibody design and development for increased specificity and efficacy while reducing side effects.2

Scientists have created multispecific antibodies with the ability to bind two or more different antigens or two or more different epitopes on the same antigen for novel applications, benefitting from physically linked multitargeting in a single therapeutic. 

Compared to monoclonal therapeutics, researchers face additional challenges during the different stages of multispecific antibody discovery and development.2 Scientists address increased complexity of multitargeting with high quality target proteins, such as CD3, multipass transmembrane, and immune checkpoint proteins from Sino Biological. High quality targets accelerate translational multispecific antibody research for clinical applications and support researchers through each stage of discovery and development.


  1. de la Torre BG, Albericio F. Molecules. 2022;27(3):1075.
  2. Labrijn AF, et al. Nat Rev Drug Discov. 2019;18(8):585-608.
Learn More